As per MRFR analysis, the India Peripheral Neuropathy Market Size was estimated at $95.6$ (USD Million) in 2023. The India Peripheral Neuropathy Market is expected to grow from $100.8$ (USD Million) in 2024 to $402$ (USD Million) by 2035. The India Peripheral Neuropathy Market CAGR (growth rate) is expected to be around $13.401\%$ during the forecast period (2025 - 2035).
The rising incidence of diabetes and other lifestyle-related conditions is driving notable developments in the India peripheral neuropathy market. There is an increasing need for efficient treatment alternatives as a result of the rise in diseases like diabetes, which is frequently connected to peripheral neuropathy.
In an effort to combat the growing prevalence of non-communicable diseases nationwide, government programs that emphasize healthcare access and knowledge are also fueling this trend. Additionally, the market is changing due to developments in medical technology and treatment methods, such as enhanced diagnostic tools and novel pharmaceutical therapies.
This industry has a lot of untapped potential, particularly in the areas of early diagnosis and individualized treatment plans. The pharmaceutical sector in India is thriving, and more businesses are concentrating on neurodegenerative disease research and development. This creates opportunities for cooperation between established businesses and local startups, fostering innovation.
Furthermore, as a growing number of young people are leading sedentary lives, educating people about lifestyle changes and preventative measures can result in a proactive approach to managing peripheral neuropathy. There has been a discernible trend in recent years towards telemedicine platforms and digital health solutions that make it easier for patients to receive specialized care, particularly in remote locations. The continuous advancement of e-health technologies seeks to address accessibility gaps in healthcare, facilitating prompt treatments for patients.
All things considered, the market for peripheral neuropathy in India is expanding rapidly due to a combination of rising illness prevalence and cutting-edge care and treatment methods.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising incidence of diabetes in India significantly drives the India Peripheral Neuropathy Market, as diabetic neuropathy is one of the most common complications of this disease. According to estimates from the International Diabetes Federation, India is home to over $77$ million diabetics, with projections indicating this number may rise to $134$ million by 2045.
This increasing diabetes prevalence directly correlates with a corresponding rise in peripheral neuropathy cases, as nearly $50\%$ of diabetic patients develop some form of neuropathy, leading to enhanced demand for specialized diagnostic tools and treatment options. Established organizations such as the Diabetes Foundation India and the All India Institute of Medical Sciences are also actively working on increasing awareness and providing treatment updates, which further emphasizes the urgency of addressing this burgeoning health issue.
The continuous advancements in medical technology significantly bolster the India Peripheral Neuropathy Market. Innovations in neuroimaging techniques and treatment options, including minimally invasive surgical procedures and better medications, enhance diagnostic accuracy and therapeutic efficacy.
For example, the introduction of new FDA-approved drugs tailored for neuropathic pain relief has shown improvement in patient outcomes, with clinical trials demonstrating a more than $40\%$ efficacy rate in symptom management. The Indian healthcare sector is witnessing an investment surge from both domestic and international companies, which enables healthcare professionals to evolve their practices. Key players like Biocon and Dr. Reddy's Laboratories are progressing in Research and Development (R&D) to focus on such innovations.
India's aging population is another critical driver of the India Peripheral Neuropathy Market. The elderly population in India is expected to reach approximately $300$ million by 2050, presenting a substantial market opportunity. Age-related neuropathies account for a considerable portion of peripheral neuropathy cases.
Recent statistics indicate that around $30\%$ of individuals aged 60 and older may suffer from some form of neuropathy. This growing demographic transition calls for suitable healthcare solutions tailored to their needs. Organizations like the Ministry of Health and Family Welfare highlight the necessity of improving healthcare access and specialized services for elderly patients, further promoting the market for neuropathy-related interventions.
The rise in awareness about peripheral neuropathy and its implications substantially impacts the India Peripheral Neuropathy Market. Healthcare organizations, in collaboration with government bodies, have been launching extensive awareness campaigns to educate the public and healthcare professionals about the symptoms, risk factors, and treatment options for peripheral neuropathy.
For instance, recent initiatives by the Neurological Society of India emphasize the need for early detection and intervention strategies to improve patient outcomes. As a result, the number of diagnosed cases has increased, guiding individuals toward seeking medical help and consequently increasing the demand for treatment options and diagnostic services in the market.
The India Peripheral Neuropathy Market presents a wide array of insights related to the Type segment, encompassing various forms of peripheral neuropathy that reflect significant health concerns for the population.
Among these, Diabetic Peripheral Neuropathy is particularly noteworthy as it arises from the complications of diabetes, a condition that has surged in prevalence in India due to lifestyle changes and increasing obesity rates. This form of neuropathy affects a considerable segment of the diabetic population, impacting their quality of life and productivity, thus highlighting the relevance of innovations in treatment within this segment.
Chemotherapy-induced Peripheral Neuropathy is another critical concern, stemming from the side effects of essential cancer treatments that impact a substantial number of cancer patients in India, leading to a growing focus on supportive therapies that can alleviate these effects. The Idiopathic Peripheral Neuropathy category remains enigmatic, often posing challenges in diagnosis and management, which underscores the need for more extensive research and awareness within medical communities.
Lastly, HIV/AIDS Associated Peripheral Neuropathy, while less commonly discussed, remains significant due to the ongoing efforts to manage and treat conditions arising from HIV complications in affected individuals. This reflects an essential intersection of public health initiatives and healthcare delivery systems in addressing the complex needs associated with this type of neuropathy.
Overall, understanding the nuances of each category within the India Peripheral Neuropathy Market segmentation is crucial as each one exhibits distinctive characteristics, challenges, and opportunities that play a vital role in shaping the healthcare landscape in India. These market dynamics demonstrate the increasing demand for tailored therapeutic solutions and highlight the urgency for continued research and development efforts to provide effective care for the diverse needs of individuals suffering from peripheral neuropathy across the country.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment segment of the India Peripheral Neuropathy Market is an essential component, showcasing diverse approaches that cater to the growing patient population affected by this condition. The segment encompasses various strategies, including Pharmacological Therapies, which are crucial for managing pain and improving quality of life for patients. These therapies typically involve the use of prescription medications that help in alleviating symptoms associated with neuropathic pain.
Non-Pharmacological Therapies have gained traction as well, focusing on alternative treatments like physical therapy, acupuncture, and lifestyle modification which are often favored for their fewer side effects. The combination of these therapies allows for a comprehensive treatment plan, addressing both the symptoms and underlying causes of peripheral neuropathy. The segment is characterized by ongoing Research and Development endeavors aimed at introducing innovative treatment options that meet the unique needs of patients in India.
This diversity in treatment options not only reflects the growing understanding of the condition but also highlights the opportunities for healthcare providers to personalize treatment for better patient outcomes. With an increasing prevalence of risk factors such as diabetes and the aging population in India, the Treatment segment is poised for significant growth, making it a key focus area within the India Peripheral Neuropathy Market.
The End-user segment of the India Peripheral Neuropathy Market plays a crucial role in shaping the overall landscape of healthcare dedicated to neurological conditions. Hospitals and clinics stand out as the primary settings for managing peripheral neuropathy, as they offer specialized care and advanced treatment options to patients. The prevalence of diabetes and other chronic conditions in India contributes significantly to the growing need for treatment services, leading hospitals and clinics to adapt their services to better address these demands.
Ambulatory centers are also gaining traction due to their ability to provide outpatient care, which allows for more convenient and accessible treatments for patients dealing with peripheral neuropathy. This shift towards outpatient services often results in higher patient throughput and reduced wait times, creating an appealing option for many individuals. Additionally, other End-users, such as rehabilitation facilities, provide essential support services that cater to patients' recovery processes and improve quality of life. With the increasing awareness and the need for early intervention strategies, these varied settings significantly influence the India Peripheral Neuropathy Market dynamics, fostering opportunities for innovation and improvement in patient care.
The India Peripheral Neuropathy Market has been evolving rapidly due to increasing awareness regarding neurological disorders and advances in healthcare. The market is characterized by a variety of stakeholders, including pharmaceutical companies, healthcare providers, and patients seeking effective treatment solutions for peripheral neuropathy. Factors contributing to the market's growth include a rise in chronic diseases such as diabetes, which is a leading cause of peripheral nerve damage, alongside an aging population more prone to neurological ailments.
In recent years, there has been a significant push towards innovative treatment options that include medication, physical therapy, and alternative therapies, creating a competitive landscape where firms are striving to gain market share. The interplay of these elements leads to a dynamic environment where companies must navigate the regulatory frameworks while responding to the changing needs of patients.
Zydus Cadila has established a solid foothold in the India Peripheral Neuropathy Market through its extensive portfolio of therapeutic offerings. The company is recognized for its commitment to research and development, which empowers it to innovate and provide effective treatment options in managing peripheral neuropathy. This proactive approach enhances Zydus Cadila's market presence as they strategically collaborate with healthcare providers and stakeholders to ensure that their products are accessible to patients. Their manufacturing capabilities and experience in the pharmaceutical sector add to their strengths, affording them the agility to respond to market demands effectively. Zydus Cadila's reputation for quality and reliability further cements its position as a significant player in managing neurological disorders within India.
Pfizer also possesses a notable presence in the India Peripheral Neuropathy Market with a diverse range of products that cater to the needs of patients suffering from peripheral nerve damage. The company's focus on neurological treatments, including research-driven solutions and established medications, underscores its strategic intent to provide quality care for patients. Pfizer's strengths lie in its financial stability, extensive distribution networks, and strong relationships with healthcare professionals that enable it to reach a broad demographic. The company's emphasis on innovation is supported by ongoing mergers and acquisitions, allowing it to integrate advanced technologies and expand its product offerings in the market. As such, Pfizer is well-positioned to capitalize on the growing demand for effective therapies in the area of peripheral neuropathy, working closely with stakeholders to contribute to improved health outcomes across India.
The India Peripheral Neuropathy Market has seen significant developments recently, fueled by an increasing prevalence of diabetes and related neurological disorders. Notably, companies such as Zydus Cadila, Cipla, and Dr. Reddy's Laboratories have been expanding their product portfolios to include innovative therapies and diagnostics to address peripheral neuropathy.
In June 2023, Pfizer announced a partnership with local biotech firms to enhance Research and Development for neuropathic pain remedies, which is expected to accelerate drug availability. Additionally, Sun Pharmaceutical Industries reported an increase in revenue due to the growing demand for peripheral neuropathy treatments, highlighting a robust growth trajectory within the market. Merck and Co. completed the acquisition of a small Indian biopharmaceutical firm in July 2023 to bolster its foothold in the neurology segment. Over the past two years, there has been an increase in Mylan's product offerings for neuropathy treatment, with new generics launched in early 2023 following regulatory approvals.
The market's valuation is poised for further growth as companies innovate and invest in therapeutic options, reflecting a broader trend towards enhancing patient care in India’s evolving healthcare landscape.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 95.6(USD Million) |
| MARKET SIZE 2024 | 100.8(USD Million) |
| MARKET SIZE 2035 | 402.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.401% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Zydus Cadila, Pfizer, Tata Consultancy Services, Cipla, Dr. Reddy's Laboratories, Merck & Co., Sun Pharmaceutical Industries, Mylan, Abbott Laboratories, AstraZeneca, Apex Healthcare Berhad, BristolMyers Squibb, Johnson & Johnson, Sanofi, Novartis |
| SEGMENTS COVERED | Type, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Rising diabetes prevalence, Increasing elderly population, Advancements in treatment options, Growing demand for neuropathy diagnostics, Expansion of telehealth services |
| KEY MARKET DYNAMICS | Increasing diabetes prevalence, Aging population, Innovative treatment options, Growing awareness campaigns, Rising demand for diagnostics |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Peripheral Neuropathy Market is expected to be valued at 100.8 million USD in 2024.
By 2035, the market is anticipated to reach a value of 402.0 million USD.
The anticipated CAGR for the India Peripheral Neuropathy Market from 2025 to 2035 is 13.401%.
Diabetic Peripheral Neuropathy holds the largest market share, valued at 45.0 million USD in 2024.
The market for Chemotherapy-induced Peripheral Neuropathy is projected to reach 100.0 million USD by 2035.
Major players include Zydus Cadila, Pfizer, Cipla, and Dr. Reddy's Laboratories, among others.
The market size for Idiopathic Peripheral Neuropathy is expected to be 60.0 million USD in 2035.
Yes, it is anticipated to grow to a market value of 62.0 million USD by 2035.
The market is driven by increasing prevalence of diabetes and awareness about peripheral neuropathy.
The market is expected to experience significant growth post-2025, influenced by advancements in treatment options.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
